Seaport Therapeutics
Phase II3 active candidates
same indication: Headache Disorders (Cluster & Migraine)Phase II peer2 overlapping stagessame regulator: US FDA
Back to StakeholdersProgramme tracker View landscape
Lead program: Phase II
Categories
1 domain / 2 areas / 1 specialization
Bright Minds BiosciencesNASDAQ: DRUG
Data updated
3 Drug Candidates
Bright Minds Biosciences (NASDAQ: DRUG) is a Vancouver-based biotech developing highly selective serotonergic agonists for neurological and psychiatric disorders. Lead asset BMB-101, a 5-HT2C agonist, is in Phase 2 for drug-resistant epilepsy (BREAKTHROUGH study, positive Phase 2 results January 2026). BMB-201 is a 5-HT2A/2C agonist showing preclinical efficacy in pain and migraine models (outperformed sumatriptan, Sept 2025). BMB-202 is a selective 5-HT2A agonist with antidepressant profile in development for MDD.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 3
- Active programmes
- 3
- Lead stage
- Phase II
- Forecast coverage
- 3 of 3
All tracked candidates active
All tracked programmes active
Multiple active stages
3 active programmes with forecast fields
Latest sourced update
Bright Minds Biosciences Pipeline
Jun 27, 2026 - company-website - Bright Minds Biosciences - BMB-101
Next known catalyst
Phase III started
Timing not specified - BMB-101 / BREAKTHROUGH — BMB-101 Phase 2 (Absence Epilepsy / DEE) - Confidence: 50%
7 sources0 pipeline-linked trials0 pipeline-linked papers1 Phase II2 Preclinical
Development Programmes
3BMB-101
Phase II
BMB-101 is a highly selective 5-HT2C receptor agonist (>100-fold selectivity over 5-HT2A and 5-HT2B) and biased Gq agonist, administered orally twice daily. Indication: absence epilepsy and Developmental Epileptic Encephalopathy (DEE), including Dravet Syndrome, Lennox-Gastaut, Pitt-Hopkins, Prader-Willi, and Rett syndromes. Phase 2 BREAKTHROUGH Study (NCT06401538): positive topline January 6, 2026 — 73.1% median reduction in absence seizures, 63.3% reduction in major motor seizures. Global registrational trials being planned. Note: not related to cluster headaches — that indication is being explored for BMB-201.
Programme Tracker
BREAKTHROUGH — BMB-101 Phase 2 (Absence Epilepsy / DEE)
Primary: US (FDA)
Phase IIActive
Forecast
Phase III started - Approval eventual: 45%
Phase 2 BREAKTHROUGH positive (Jan 2026). Preparing global registrational programme for absence seizures and DEE. Phase 2 in Prader-Willi syndrome planned Q1 2026.
Milestones
Phase II started
CompletedActual: Sep 1, 2024
BREAKTHROUGH Phase 2 study (NCT06401538) initiated — first-in-patient study of selective 5-HT2C agonist for absence epilepsy and DEE
Why it matters: First Phase 2 test of 5-HT2C selective mechanism in treatment-resistant epilepsy; mechanism distinct from any approved anti-seizure medication
Watch next: Topline seizure reduction data
Phase II topline
CompletedActual: Jan 6, 2026
BREAKTHROUGH Phase 2 positive topline: 73.1% median reduction in absence seizures; 63.3% median reduction in major motor seizures; favorable safety and tolerability across DEE subtypes
Why it matters: Large seizure reductions in a highly treatment-resistant population; 5-HT2C mechanism validated clinically for the first time in epilepsy
Watch next: Global registrational programme design; Phase 2 in Prader-Willi
Recorded Events
Jan 6, 2026: Phase II topline
Sep 1, 2024: Phase II started
Evidence Links
NCT06401538 — BREAKTHROUGH Phase 2 (BMB-101, Absence Epilepsy/DEE)
trial-registry - ClinicalTrials.gov - Aug 12, 2025 - Verified
Bright Minds Biosciences Pipeline
company-website - Bright Minds Biosciences - Jun 27, 2026 - Verified
BMB-201
Preclinical
BMB-201 is a mixed 5-HT2A/2C receptor agonist for pain and headache indications. Preclinical: outperformed sumatriptan in validated vascular headache model (September 2025); similar efficacy to morphine in NIH pain screening models (October 2024). IND-enabling studies planned.
Programme Tracker
Headache Disorders (Cluster & Migraine)
Primary: US (FDA)
Pre-clinicalActive
Forecast
preclinical-data
Positive preclinical pain and vascular-headache data support advancement toward clinical development. No IND filing or human-study start was found in the June 2026 sweep, so the next watch item remains additional preclinical/IND-enabling disclosure or a clinical-trial start announcement.
Milestones
Pre-clinical completed
CompletedActual: Sep 4, 2025
BMB-201 outperformed sumatriptan in validated preclinical vascular headache model (isosorbide dinitrate rat model): superior reductions in facial mechanical allodynia vs. sumatriptan
Why it matters: Headache/migraine is a large underserved indication; BMB-201's mixed 5-HT2A/2C profile may provide analgesia and anti-migraine effects without hallucinogenic 5-HT2A activation
Watch next: IND-enabling studies and first-in-human Phase 1
Recorded Events
Sep 4, 2025: Pre-clinical completed
Evidence Links
Bright Minds Biosciences Pipeline
company-website - Bright Minds Biosciences - Jun 26, 2026 - Verified
BMB-202
Preclinical
BMB-202 is a highly selective 5-HT2A agonist (>30-fold over 5-HT2C, >500-fold over 5-HT2B) for depression. Fast Cmax-driven profile designed for shorter psychedelic duration. Phase 1 originally planned for late 2023; current status not prominently featured in 2025-2026 communications.
Programme Tracker
Depressive Disorders
Primary: US (FDA)
Pre-clinicalActive
Forecast
Pre-clinical completed
Preclinical 5-HT2A agonist for depression. Bright Minds’ recent communications emphasize BMB-101 and BMB-201; no clinical-stage BMB-202 update was found in June 2026 checks.
Milestones
Pre-clinical started
CompletedActual: Apr 19, 2023
International Searching Authority issued a favorable written opinion on Bright Minds’ patent application covering BMB-202 and related phenethylamine compounds.
Why it matters: Supports patentability around the 5-HT2A programme, but does not itself indicate clinical readiness.
Watch next: IND-enabling update, Phase 1 start, or deprioritization signal relative to BMB-101/BMB-201.
Recorded Events
Apr 19, 2023: Pre-clinical started
Evidence Links
Bright Minds Receives Favorable International Searching Authority Opinion for BMB-202
Press release - Bright Minds Biosciences - Apr 19, 2023 - Verified
Psychedelic Alpha — Psychedelic Drug Development Tracker
industry-media - Psychedelic Alpha - Jun 26, 2026 - Verified
Q1 2026 tracker lists BMB-202 as a discovery/preclinical 5-HT2A agonist for depression.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
AbbVie
Phase II2 active candidates
same indication: Depressive DisordersPhase II peer2 overlapping stagessame regulator: US FDA
Ceruvia Lifesciences
Phase II2 active candidates2 trials
same indication: Headache Disorders (Cluster & Migraine)Phase II peersame regulator: US FDAsimilar active pipeline size
Reunion Neuroscience
Phase III4 active candidates
same indication: Depressive Disorders2 overlapping stagessame regulator: US FDAsimilar active pipeline size
Quick Facts
- Type
- Public Biotech
- Ticker
- NASDAQ: DRUG
- Lead Stage
- Phase II
- Website
- Visit